Brentuximab Vedotin
Brentuximab vedotin is a targeted cancer therapy used primarily to treat specific types of lymphoma, a cancer of the lymphatic system. It combines an antibody that recognizes cancer cells with a powerful chemotherapy drug. The antibody attaches to the cancer cells and delivers the chemotherapy directly to them, which helps kill the cancer without harming too much of the surrounding healthy tissue. This approach aims to improve treatment effectiveness while reducing side effects compared to traditional chemotherapy methods. Brentuximab vedotin has shown promise in treating certain cases of Hodgkin lymphoma and non-Hodgkin lymphoma.
Additional Insights
-
Brentuximab vedotin is a targeted cancer therapy used primarily to treat certain types of lymphoma, including Hodgkin lymphoma and anaplastic large cell lymphoma. It combines an antibody that specifically targets cancer cells with a powerful chemotherapy drug. The antibody attaches to cancer cells, delivering the chemotherapy directly to them, which helps to kill the cells while minimizing damage to healthy tissue. This approach aims to improve treatment efficacy and reduce side effects compared to traditional chemotherapy. Brentuximab vedotin is typically used when other treatments have not been successful.